RVNC News and Press, Revance Therapeutics Inc. From 11/24/20

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer, Mark Foley, will participate in a fireside chat at the Piper Sandler 32nd Annual...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. A ho...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2020 Virtual Healthcare Conference, a fully virtual management access conference, taking place No...

Revance Therapeutics (RVNC) down 6% in premarket on results from its Phase 2 trial evaluating daxibotulinumtoxinA for Injection for the management of plantar fasciitis, a common source of heel pain.The study at both doses, failed to meet the primary efficacy endpoint of&#x...

Revance Therapeutics, Inc. (RVNC) Q3 2020 Earnings Conference Call November 09, 2020 4:30 PM ET Company Participants Jeanie Herbert - Head of Investor Relations Mark Foley - President & Chief Executive Officer Toby Schilke - Chief Financial Officer Dustin Sjuts - Chief Commercial Officer,...

Revance Therapeutics (RVNC): Q3 GAAP EPS of -$1.34 misses by $0.30.Revenue of $3.8M (+7500.0% Y/Y) beats by $2.09M.FY20 guidance: GAAP operating expense of $285M-295M;  non-GAAP operating expense of $220M-230M; non-GAAP research and development expense of $95M-100M.Shares -5.8%.Pres...

- Patients reported significant pain reduction that was numerically greater than placebo, however, the primary efficacy endpoint was not met – Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offeri...

- Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the quarter ended September 30, 2020, and provided a corpo...